New combo therapy shows promise for rare melanoma
NCT ID NCT05384496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, axitinib and nivolumab, can shrink or control advanced mucosal melanoma that hasn't been treated before. About 20 adults with this rare cancer will receive the combination. The goal is to see if the drugs work better together than alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
- New drug cocktail targets rare, aggressive melanoma
- Can a vaccine keep melanoma from coming back? large trial tests immune boosters
- New drug KUP-101A enters first human tests for advanced skin cancers
- Triple drug attack on melanoma: new trial hopes to boost surgery success
- New drug duo aims to fight rare melanoma before surgery